Cannabinoid-opioid interactions in drug discrimination and self-administration: Effect of maternal, postnatal, adolescent and adult exposure to the drugs

Current Drug Targets

Volumn 11, Issue 4, 2010, Pages 450-461

  Spano, M S ^a   Fadda, P ^a   Fratta, W ^a,b   Fattore, L ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

Author keywords

Adolescence; Cannabinoid; Drug discrimination; Gateway hypothesis; Opioid; Reward; Self administration; Vulnerability

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; DRONABINOL; METHYLLYCACONITINE; NALTREXONE; OPIATE; RIMONABANT;

BRAIN DEVELOPMENT; DRUG ABUSE; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG SELF ADMINISTRATION; GESTATION PERIOD; HUMAN; NEUROBIOLOGY; NEUROPHARMACOLOGY; NONHUMAN; PERINATAL PERIOD; REVIEW;

ADOLESCENT; ADULT; AGE FACTORS; ANIMALS; BEHAVIOR, ADDICTIVE; BRAIN; DISCRIMINATION (PSYCHOLOGY); ENDOCANNABINOIDS; FEMALE; GESTATIONAL AGE; HUMANS; MALE; MARIJUANA ABUSE; OPIOID PEPTIDES; OPIOID-RELATED DISORDERS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, MU; RECURRENCE; REINFORCEMENT (PSYCHOLOGY); REWARD; RISK FACTORS; SELF MEDICATION; YOUNG ADULT;

EID: 77950808401     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790980295     Document Type: Review

References (167)

1. Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 1999; 347: 183-190 (Pubitemid 30001667)
2. Kirkham TC, Williams CM. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology 2001; 153: 267-270
3. Verty AN, Singh ME, McGregor IS, Mallet PE. The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology 2003; 168: 314-323
4. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004; 74: 1317-1324
5. Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol 2006; 4: 239-257
6. Kirkham TC, Tucci SA. Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets 2006; 5: 272-292
7. Read SJ, Dray A. Osteoarthritic pain: a review of current, theoretical and emerging therapeutics. Expert Opin Investig Drugs 2008; 17: 619-640
8. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 1990; 102: 156-162
9. Ng Cheong Ton JM, Gerhardt GA, Friedemann M, Etgen AM, Rose GM, Sharpless NS, Gardner EL The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Res 1988; 451: 59-68.
10. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997; 8: 649-652
11. Gessa GL, Melis M, Muntoni AL, Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998; 341: 39-44.
12. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, van Gerven JM, Ramsey NF, Lammertsma AA, Kahn RS. Delta 9- tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009; 34: 759-766
13. Maldonado R, Saiardi A, Valverde O, Samad TA, Roques BP, Borrelli E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 1997; 388: 586-589 (Pubitemid 27340008)
14. Koob GF, Nestler EJ. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci 1997; 9: 482-497
15. Manzanares J, Corchero J, Romero J, Fernández-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999; 20: 287-294
16. Fattore L, Cossu G, Spano MS, Deiana S, Fadda P, Scherma M, Fratta W. Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol 2004; 16:147-158
17. Fattore L, Deiana S, Spano SM, Cossu G, Fadda P, Scherma M, Fratta W. Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol Biochem Behav 2005; 81: 343-359
18. Robledo P, Berrendero F, Ozaita A, Maldonado R. Advances in the field of cannabinoid--opioid cross-talk. Addict Biol 2008; 13: 213-224
19. Haney M, Bisaga A, Foltin RW. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology 2003; 166: 77-85.
20. Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 2007; 32: 1391-1403
21. Mailleux P, Vanderhaeghen JJ. Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci Lett 1992; 148: 173-176
22. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridisation histochemistry. Neuroscience 1992; 48: 655-668
23. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005; 168: 299-325.
24. Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 2001; 21: 823-833
25. Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Akil H, Watson SJ. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 1994; 350: 412-438
26. Voorn P, Brady LS, Berendse HW, Richfield EK. Densitometrical analysis of opioid receptor ligand binding in the human striatum - I. Distribution of mu opioid receptor defines shell and core of the ventral striatum. Neuroscience 1996; 75: 777-792
27. Pickel VM, Chan J, Kash TL, Rodríguez JJ, Mackie K. Compartment-specific localization of cannabinoid 1 (CB1) and muopioid receptors in rat nucleus accumbens. Neuroscience 2004; 127: 101-112
28. Caillé S, Parsons LH. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology 2006; 31: 804-813
29. Pontieri FE, Monnazzi P, Scontrini A, Buttarelli FR, Patacchioli FR. Behavioral sensitisation to heroin by cannabinoid pretreatment in the rat. Eur J Pharmacol 2001; 421: R1-3.
30. Pontieri FE, Monnazzi P, Scontrini A, Buttarelli FR, Patacchioli FR. Behavioral sensitisation to WIN55212.2 in rats pretreated with heroin. Brain Res 2001; 898: 178-180
31. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G. Behavioural sensitisation after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitisation with morphine. Psychopharmacology 2001; 158: 259-266
32. Lamarque S, Taghzouti K, Simon H. Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 2001; 41: 118-129
33. Braida D, Pozzi M, Parolaro D, Sala M. Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur J Pharmacol 2001; 413: 227-234
34. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gomez R, del Arco I, Villanua MA, Maldonado R, Koob GF, Rodriguez de Fonseca F. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 2001; 21: 5344-5350
35. De Vries TJ, Homberg JR, Binnekade R, Raasø H, Schoffelmeer AN. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 2003; 168: 164-169
36. Fattore L, Cossu G, Mascia MS, Obinu MC, Ledent C, Parmentier M, Imperato A, Böhme GA, Fratta W. Role of cannabinoid CB1 receptor in morphine rewarding effects in mice. Pharm Pharmacol Commun 2000; 6: 1-6.
37. Fattore L, Cossu G, Fratta W. Functional interaction between cannabinoids and opioids in animal models of drug addiction. Proceedings of the "Frontiers in Addiction Research 2002". NIDA Symposium Satellite at the SfN Meeting, 2002.
38. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 2003; 306: 93-102.
39. Braida D, Pozzi M, Cavallini R, Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 2001; 104: 923-926
40. Singh ME, Verty AN, McGregor IS, Mallet PE. A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitisation to morphine. Brain Res 2004; 1026: 244-253
41. Azizi P, Haghparast A, Hassanpour-Ezatti M. Effects of CB1 receptor antagonist within the nucleus accumbens on the acquisition and expression of morphine-induced conditioned place preference in morphine-sensitised rats. Behav Brain Res 2008; 197: 119-124
42. Solinas M, Zangen A, Thiriet N, Goldberg SR. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9-tetrahydrocannabinol. Eur J Neurosci 2004; 19: 3183-3192
43. Solinas M, Goldberg SR. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9- tetrahydrocannabinol (THC) in rats. Psychopharmacology 2005; 179: 804-812
44. Valverde O, Noble F, Beslot F, Daugé V, Fournié-Zaluski MC, Roques BP. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 2001; 13: 1816-1824
45. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 2002; 22: 1146-1154
46. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T Roques BP, Vassart G, Fratta W, Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401-404
47. Cossu G, Ledent C, Fattore L, Imperato A, Böhme GA, Parmentier M, Fratta W. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 2001; 118: 61-65
48. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitisation to locomotor responses in CB1 knockout mice. Eur J Neurosci 2000; 12: 4038-4046
49. Rice OV, Gordon N, Gifford AN. Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice. Brain Res 2002; 945: 135-138
50. Laviola G, Adriani W, Terranova ML, Gerra G. Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. Neurosci Biobehav Rev 1999; 23: 993-1010.
51. Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 2003; 160: 1041-1052
52. Barron S, White A, Swartzwelder HS, Bell RL, Rodd ZA, Slawecki CJ, Ehlers CL, Levin ED, Rezvani AH, Spear LP. Adolescent vulnerabilities to chronic alcohol or nicotine exposure: findings from rodent models. Alcohol Clin Exp Res 2005; 29: 1720-1725
53. Yamaguchi K, Kandel DB. Patterns of drug use from adolescence to young adulthood: III. Predictors of progression. Am J Public Health 1984; 74: 673-681 (Pubitemid 14119524)
54. Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, Gigerenzer G, Hoehe MR. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 1999; 142: 295-301.
55. Pope HG Jr, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 2003; 69: 303-310
56. Hall WD. Cannabis use and the mental health of young people. Aust NZJ Psychiatry 2006; 40: 105-113
57. Verkooijen KT, de Vries NK, Nielsen GA. Youth crowds and substance use: the impact of perceived group norm and multiple group identification. Psychol Addict Behav 2007; 21: 55-61.
58. Spear LP. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 2000; 24: 417-463
59. McCarthy MM, Amateau SK, Mong JA. Steroid modulation of astrocytes in the neonatal brain: implications for adult reproductive function. Biol Reprod 2002; 67: 691-698
60. Giedd JN, Jeffries NO, Blumenthal J, Castellanos FX, Vaituzis AC, Fernandez T, Hamburger SD, Liu H, Nelson J, Bedwell J, Tran L, Lenane M, Nicolson R, Rapoport JL. Childhood-onset schizophrenia: progressive brain changes during adolescence. Biol Psychiatry 1999; 46: 892-898
61. Salzet M. Invertebrate molecular neuroimmune processes. Brain Res Rev 2000; 34: 69-79.
62. Zanardo V, Nicolussi S, Carlo G, Marzari F, Faggian D, Favaro F, Plebani M. Beta endorphin concentrations in human milk. J Pediatr Gastroenterol Nutr 2001; 33: 160-164 (Pubitemid 32802813)
63. Fride E. Multiple roles for the endocannabinoid system during the earliest stages of life: pre- and postnatal development. J Neuroendocrinol 2008; 20: 75-81. (Pubitemid 351552680)
64. Loughlin SE, Massamiri TR, Kornblum HI, Leslie FM. Postnatal development of opioid systems in rat brain. Neuropeptides 1985; 5: 469-472 (Pubitemid 15139758)
65. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995; 18: 22-29
66. Wang H, Wessendorf MW. Mu- and delta-opioid receptor mRNAs are expressed in periaqueductal gray neurons projecting to the rostral ventromedial medulla. Neuroscience 2002; 109: 619-634 (Pubitemid 34122010)
67. Wittert G, Hope P, Pyle D. Tissue distribution of opioid receptor gene expression in the rat. Biochem Biophys Res Commun 1996; 218: 877-881 (Pubitemid 26050757)
68. Xia Y, Haddad GG. Ontogeny and distribution of opioid receptors in the rat brainstem. Brain Res 1991; 549: 181-193
69. Coyle JT, Pert CB. Ontogenetic development of [3H]naloxone binding in rat brain. Neuropharmacology 1976; 15: 555-560
70. Pert CB, Kuhar MJ, Snyder SH. Opiate receptor: autoradiographic localization in rat brain. Proc Natl Acad Sci 1976; 73: 3729-3733
71. Atweh SF, Kuhar MJ. Autoradiographic localization of opiate receptors in rat brain. II. The brain stem. Brain Res 1977; 129: 1-12.
72. Kent JL, Pert CB, Herkenham M. Ontogeny of opiate receptors in rat forebrain: visualization by in vitro autoradiography. Brain Res 1981; 254; 487-504. (Pubitemid 12175364)
73. Recht LD, Kent J, Pasternak GW. Quantitative autoradiography of the development of mu opiate binding sites in rat brain. Cell Mol Neurobiol 1985; 5: 223-229 (Pubitemid 16214402)
74. Marsh DF, Hatch DJ, Fitzgerald M. Opioid systems and the newborn. Br J Anaesth 1997; 79: 787-795
75. Fernández-Ruiz J, Gómez M, Hernández M, de Miguel R, Ramos JA. Cannabinoids and gene expression during brain development. Neurotox Res 2004; 6: 389-401.
76. Wang X, Dow-Edwards D, Anderson V, Minkoff H, Hurd YL. Discrete opioid gene expression impairment in the human foetal brain associated with maternal marijuana use. Pharmacogenomics J 2006; 6: 255-264 (Pubitemid 44137952)
77. Pérez-Rosado A, Manzanares J, Fernández-Ruiz J, Ramos JA. Prenatal Delta(9)-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the foetal rat brain: sex-dependent differences. Brain Res Dev 2000; 120: 77-81.
78. Vela G, Martín S, García-Gil L, Crespo JA, Ruiz-Gayo M, Fernández-Ruiz JJ, García-Lecumberri C, Pélaprat D, Fuentes JA, Ramos JA, Ambrosio E. Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central mu opioid receptors in adult offspring female rats. Brain Res 1998; 807: 101-109
79. Ellgren M, Spano SM, Hurd YL. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 2007; 32: 607-615 (Pubitemid 46271055)
80. Biscaia M, Fernández B, Higuera-Matas A, Miguéns M, Viveros MP, García-Lecumberri C, Ambrosio E. Sex-dependent effects of periadolescent exposure to the cannabinoid agonist CP-55,940 on morphine self-administration behaviour and the endogenous opioid system. Neuropharmacology 2008; 54: 863-873
81. Pistis M, Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL. Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry 2004; 56: 86-94. (Pubitemid 38849412)
82. Corchero J, Manzanares J, Fuentes JA. Repeated administration of delta9-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat. Neuropharmacology 1999; 38: 433-439 (Pubitemid 29097726)
83. Corchero J, Oliva JM, García-Lecumberri C, Martin S, Ambrosio E, Manzanares JJ. Repeated administration with Delta9-tetrahydrocannabinol regulates mu-opioid receptor density in the rat brain. J Psychopharmacology 2004; 18: 54-58 (Pubitemid 38623094)
84. Viganò D, Rubino T, Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 2005; 81: 360-368 (Pubitemid 40807133)
85. Fattore L, Viganò D, Fadda P, Rubino T, Fratta W, Parolaro D. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci 2007; 25: 2191-2200 (Pubitemid 46581742)
86. Salzet M, Vieau D, Day R. Crosstalk between nervous and immune systems through the animal kingdom: focus on opioids. Trends Neurosci 2000; 23: 550-555
87. Rodríguez de Fonseca F, Ramos JA, Bonnin A, Fernández-Ruiz JJ. Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 1993; 4: 135-138
88. Wang X, Dow-Edwards D, Keller E, Hurd YL. Preferential limbic expression of the cannabinoid receptor mRNA in the human foetal brain. Neuroscience 2003; 118: 681-694
89. Rubino T, Tizzoni L, Viganò D, Massi P, Parolaro D. Modulation of rat brain cannabinoid receptors after chronic morphine treatment. Neuroreport 1997; 8: 3219-3223 (Pubitemid 27461370)
90. González S, Fernandez-Ruiz J, Sparpaglione V, Parolaro D, Ramos JA. Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend 2002; 66: 77-84.
91. González S, Schmid PC, Fernández-Ruiz J, Krebsbach R, Schmid HH, Ramos JA. Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats. Addict Biol 2003; 8: 159-166
92. Viganò D, Valenti M, Cascio MG, Di Marzo V, Parolaro D, Rubino T. Changes in endocannabinoid levels in a rat model of behavioural sensitisation to morphine. Eur J Neurosci 2004; 20: 1849-1857
93. Caillé S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci 2007; 27: 3695-3702
94. Manzanedo C, Aguilar MA, Rodríguez-Arias M, Navarro M, Miñarro J. Cannabinoid agonist-induced sensitisation to morphine place preference in mice. Neuroreport 2004; 15: 1373-1377
95. Jardinaud F, Roques BP, Noble F. Tolerance to the reinforcing effects of morphine in delta9-tetrahydrocannabinol treated mice. Behav Brain Res 2006; 173: 255-261
96. Ayhan IH, Kaymakçalan S, Tulunay FC. Interaction between delta 9-tetrahydrocannabinol and morphine on the motor activity of mice. Psychopharmacology 1979; 63: 169-172
97. Hagues G, Costentin J, Duterte-Boucher D. Modulation of morphine and alcohol motor stimulant effects by cannabinoid receptors ligands. Behav Brain Res 2007; 178: 274-282
98. Fattore L, Spano MS, Cossu G, Deiana S, Fratta W. Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 2003; 17: 1723-1726
99. Fattore L, Spano MS, Cossu G, Deiana S, Fadda P, Fratta W. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology 2005; 48: 1097-1104
100. Fattore L, Fadda P, Fratta W. Endocannabinoid regulation of relapse mechanisms. Pharmacol Res 2007; 56: 418-427
101. Spano MS, Fattore L, Cossu G, Deiana S, Fadda P, Fratta W. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. Br J Pharmacol 2004; 143: 343-350
102. Stolerman IP, Rasul F, Shine PJ. Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987. Psychopharmacology 1989; 98: 1-19.
103. Colpaert FC. Drug discrimination in neurobiology. Pharmacol Biochem Behav 1999; 64, 337-345
104. Holtzman SG. Drug discrimination studies. Drug Alcohol Depend 1985; 14: 263-282
105. Rowlett JK, Spealman RD, Platt DM. Cocaine-like discriminative stimulus effects of heroin in squirrel monkeys: role of active metabolites and opioid receptor mechanisms. Psychopharmacology 2000; 150: 191-199
106. Carter RB, Leander JD. Discriminative stimulus properties of naloxone. Psychopharmacology 1982; 77: 305-308
107. White JM, Holtzman SG. Three-choice drug discrimination in the rat: morphine, cyclazocine and saline. J Pharmacol Exp Ther 1981; 217: 254-262
108. Henriksson BG, Johansson JO, Järbe TU. Delta 9-tetrahydrocannabinol produced discrimination in pigeons. Pharmacol Biochem Behav 1975; 3: 771-774
109. Järbe TU, Henriksson BG, Ohlin GC. Delta9-THC as a discriminative cue in pigeons: effects of delta8-THC, CBD, and CBN. Arch Int Pharmacodyn Ther 1977; 228: 68-72.
110. Gold LH, Balster RL, Barrett RL, Britt DT, Martin BR. A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. J Pharmacol Exp Ther 1992; 262: 479-486
111. Wiley JL, Golden KM, Ryan WJ, Balster RL, Razdan RK, Martin BR. Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. Pharmacol Biochem Behav 1997; 58: 1139-1143
112. Järbe TU, Lamb RJ, Liu Q, Makriyannis A. Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356). Psychopharmacology 2006; 188: 315-323
113. Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 1995; 34: 669-676
114. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 2008; 94: 191-198
115. Martin BR, Compton DR, Prescott WR, Barrett RL, Razdan RK. Pharmacological evaluation of dimethylheptyl analogs of delta 9-THC: reassessment of the putative three-point cannabinoid-receptor interaction. Drug Alcohol Depend 1995; 37: 231-240
116. McMahon LR, Ginsburg BC, Lamb RJ. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)- tetrahydrocannabinol in C57BL/6J mice. Psychopharmacology 2008; 198: 487-495
117. Barrett RL, Wiley JL, Balster RL, Martin BR. Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats. Psychopharmacology 1995; 118: 419-424
118. De Vry J, Jentzsch KR. Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat. Eur J Pharmacol 2004; 505: 127-133
119. Järbe TU, Mathis DA. Discriminative stimulus functions of cannabinoids/ cannabimimetics. NIDA Res Monogr 2006; 116: 75-99.
120. Mokler DJ, Nelson BD, Harris LS, Rosecrans JA. The role of benzodiazepine receptors in the discriminative stimulus properties of delta-9- tetrahydrocannabinol. Life Sci 1986; 38: 1581-1589
121. Chait LD, Evans SM, Grant KA, Kamien JB, Johanson CE, Schuster CR. Discriminative stimulus and subjective effects of smoked marijuana in humans. Psychopharmacology 1988; 94: 206-212
122. Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 2000; 59: 261-275
123. Wachtel SR, de Wit H. Naltrexone does not block the subjective effects of oral Delta(9)-tetrahydrocannabinol in humans. Drug Alcohol Depend 2000; 59: 251-260
124. Solinas M, Panlilio LV, Goldberg SR. Exposure to delta-9- tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin's reinforcing efficacy: a self-administration study in rats. Neuropsychopharmacology 2004; 29: 1301-1311
125. Self DW, Stein L. Receptor subtypes in opioid and stimulant reward. Pharmacol Toxicol 1992; 70: 87-94.
126. Herz A. Opioid reward mechanisms: a key role in drug abuse? Can J Physiol Pharmacol 1998; 76: 252-258
127. Li JX, McMahon LR, Gerak LR, Becker GL, France CP. Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception. Psychopharmacology 2008; 199: 199-208.
128. Lile JA, Kelly TH, Pinsky DJ, Hays L.R. Substitution profile of Delta(9)-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta(9)-tetrahydrocannabinol. Psychopharmacology 2009; 203: 241-250
129. Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, Walsh SL. The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 2008; 96: 1-15.
130. Dai S, Corrigall WA, Coen KM, Kalant H. Heroin self-administration by rats: influence of dose and physical dependence. Pharmacol Biochem Behav 1989; 32: 1009-1015
131. Gratton A. In vivo analysis of the role of dopamine in stimulant and opiate self-administration. J Psychiatry Neurosci 1996; 21: 264-279
132. Haney M. Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict Biol 2009; 14: 9-21.
133. Ternes JW, O'Brien CP. The opioids: abuse liability and treatments for dependence. Adv Alcohol Subs Abuse 1990; 9: 27-45.
134. Shalev U, Grimm JW, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 2002; 54: 1-42.
135. Bossert JM, Ghitza UE, Lu L, Epstein DH, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol 2005; 526: 36-50.
136. Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 1998; 85: 327-330
137. Fattore L, Cossu G, Martellotta CM, Fratta W. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology 2001; 156: 410-416
138. Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology 2003; 169: 135-140
139. Justinova Z, Solinas M, Tanda G, Redhi GH, Goldberg SR. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci 2005; 25: 5645-5650
140. Solinas M, Scherma M, Fattore L, Stroik J, Wertheim C, Tanda G, Fratta W, Goldberg SR. Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. J Neurosci 2007; 27: 5615-5620 (Pubitemid 350021063)
141. Deiana S, Fattore L, Spano MS, Cossu G, Porcu E, Fadda P, Fratta W. Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology 2007; 52: 646-654 (Pubitemid 46151687)
142. Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br J Pharmacol 2007; 152: 795-804. (Pubitemid 350034986)
143. Fadda P, Scherma M, Spano MS, Salis P, Melis V, Fattore L, Fratta W. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 2006; 17: 1629-1632 (Pubitemid 44454770)
144. Justinova Z, Tanda G, Munzar P, Goldberg SR. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys Psychopharmacology 2004; 173: 186-194
145. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 2005; 30: 2046-2057 (Pubitemid 43093504)
146. González B, de Miguel R, Martín S, Pérez-Rosado A, Romero J, García-Lecumberri C, Fernández-Ruiz J, Ramos JA, Ambrosio E. Effects of perinatal exposure to delta 9-tetrahydrocannabinol on operant morphine-reinforced behavior. Pharmacol Biochem Behav 2003; 75: 577-584 (Pubitemid 36936892)
147. Fattore L, Altea S, Fratta W. Sex differences in drug addiction: a review of animal and human studies. Women's Health 2008; 4: 51-65.
148. Spano MS, Ellgren M, Wang X, Hurd YL. Prenatal cannabis exposure increases heroin seeking with allostatic changes in limbic enkephalin systems in adulthood. Biol Psychiatry 2007; 61: 554-563 (Pubitemid 46185333)
149. Rubio P, Rodríguez de Fonseca F, Martín-Calderón JL, Del Arco I, Bartolomé S, Villanúa MA, Navarro M. Maternal exposure to low doses of delta9-tetrahydrocannabinol facilitates morphine-induced place conditioning in adult male offspring. Pharmacol Biochem Behav 1998; 61: 229-238 (Pubitemid 28498205)
150. Navarro M, Rubio P, de Fonseca FR. Behavioural consequences of maternal exposure to natural cannabinoids in rats. Psychopharmacology 1995; 122: 1-14.
151. Rubio P, Rodríguez de Fonseca F, Muñoz RM, Ariznavarreta C, Martín-Calderón JL, Navarro M. Long-term behavioral effects of perinatal exposure to delta 9-tetrahydrocannabinol in rats: possible role of pituitary-adrenal axis. Life Sci 1995; 56: 2169-2176
152. Singh ME, McGregor IS, Mallet PE. Perinatal exposure to delta(9)-tetrahydrocannabinol alters heroin-induced place conditioning and fos-immunoreactivity. Neuropsychopharmacology 2006; 31: 58-69.
153. Vela G, Fuentes JA, Bonnin A, Fernández-Ruiz J, Ruiz-Gayo M. Perinatal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) leads to changes in opioid-related behavioral patterns in rats. Brain Res 1995; 680: 142-147
154. Norwood CS, Cornish JL, Mallet PE, McGregor I.S. Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitisation and alters morphine self-administration in Lewis rats. Eur J Pharmacol 2003; 465: 105-114
155. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-784 (Pubitemid 39242829)
156. Gardner E.L. Addictive potential of cannabinoids: the underlying neurobiology. Chem Phys Lipids 2002; 121: 267-290
157. Fattore L, Fadda P, Spano MS, Pistis M, Fratta W. Neurobiological mechanisms of cannabinoid addiction. Mol Cell Endocrinol 2008; 286: S97-107.
158. Bachman JG, Johnson LD, O'Malley PM. Explaining recent increases in students' marijuana use: impacts of perceived risks and disapproval, 1976 through 1996. Am J Public Health 1998; 88: 887-892
159. Kokkevi A, Nic Gabhainn S, Spyropoulou M. Early initiation of cannabis use: a cross-national European perspective. J Adolesc Health 2006; 39: 712-719 (Pubitemid 44529027)
160. Swift W, Coffey C, Carlin JB, Degenhardt L, Patton GC. Adolescent cannabis users at 24 years: trajectories to regular weekly use and dependence in young adulthood. Addiction 2008; 103: 1361-1370 (Pubitemid 352009047)
161. Fergusson DM, Horwood, LJ. Early onset cannabis use and psychosocial adjustment in young adults. Addiction 1997; 92: 279-296
162. Grotenhermen F. The toxicology of cannabis and cannabis prohibition Chem Biodivers 2007; 4: 1744-1769
163. DeWit DJ, Hance J, Offord DR, Ogborne A. The influence of early and frequent use of marijuana on the risk of desistance and of progression to marijuana-related harm. Prev Med 2000; 31: 455-464
164. Fergusson DM, Lynskey MT, Horwood LJ. The short-term consequences of early onset cannabis use. J Abnorm Child Psychol 1996; 24: 499-512.
165. Morral AR, McCaffrey DF, Paddock SM. Reassessing the marijuana gateway effect. Addiction 2002; 97: 1493-1504
166. Kandel D, Chen K, Warner LA, Kessler RC, Grant B. Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the U.S. population. Drug Alcohol Depend 1997; 44: 11-29. (Pubitemid 27060170)
167. Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PA, Nelson EC, Statham DJ, Martin NG. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA 2003: 289: 427-433